On Wednesday, 2005 stocks advanced, 2025 declined and 168 remained unchanged on Bombay Stock Exchange with advance decline ...

Revenue up 6.7% at Rs 658 crore versus Rs 616 croreEbitda up 8.5% at Rs 85.3 crore versus Rs 78.6 croreMargin at 13% Vs 12.8%Net profit down 62.5% at Rs 1.2 crore versus Rs 3.3 croreCatch live updates ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...

Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in ...

- Mylan/Lupin Labs’ Nepexto, a biosimilar of Amgen’s Enbrel (etanercept). The CHMP meeting covered a number of line extensions for already-approved medicines as well, including: ...

Nepexto Market Report 2025 The Business Research Company's Nepexto Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 12, 2025 /E... ...